Cempra Pharmaceuticals (United States)

Recent papers from Cempra Pharmaceuticals (United States)

1. Organizing Production across Borders in a Time of UncertaintyAEA Papers and Proceedings · 2026
2. Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular DystrophyCPT Pharmacometrics & Systems Pharmacology · 2020
3. Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database StudyOpen Forum Infectious Diseases · 2020
4. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection ModelAntimicrobial Agents and Chemotherapy · 2019
5. Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology ModelingPharmaceutical Research · 2019
6. Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection—Clinical Trial Group Programmatic MeetingSexually Transmitted Diseases · 2018
7. Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic ModelsAntimicrobial Agents and Chemotherapy · 2018
8. Metabolism, Excretion, and Mass Balance of Solithromycin in HumansAntimicrobial Agents and Chemotherapy · 2018
9. The Effect of Solithromycin, a Cationic Amphiphilic Drug, on the Proliferation and Differentiation of Human Meibomian Gland Epithelial CellsCurrent Eye Research · 2017
10. Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining FluidCPT Pharmacometrics & Systems Pharmacology · 2017
11. A Phase 2A Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Haemodynamic Effects of BMS-986231 in Hospitalized Patients with Heart Failure with Reduced Ejection FractionEuropean Journal of Heart Failure · 2017
12. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort studyHospital Practice · 2017
13. Nature nurtures the design of new semi-synthetic macrolide antibioticsThe Journal of Antibiotics · 2016
14. Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjectsJournal of Antimicrobial Chemotherapy · 2016
15. Antibiotics in late clinical developmentBiochemical Pharmacology · 2016
16. A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug InteractionClinical Infectious Diseases · 2016
17. In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory PathogenAntimicrobial Agents and Chemotherapy · 2016
18. The solithromycin journey—It is all in the chemistryBioorganic & Medicinal Chemistry · 2016
19. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial PneumoniaClinical Infectious Diseases · 2016
20. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy · 2016